Chronic Optic Neuropathy in Multiple Sclerosis Clinical Trial
Official title:
CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS: DEMYELINATING AND/OR PRIMARY DEGENERATIVE PATHOPHYSIOLOGY?
| Verified date | August 2017 |
| Source | Hospices Civils de Lyon |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Patients with multiple sclerosis (MS) may show chronic signs of optic neuropathy (CON) that
may follow acute optic neuritis (secondary form of CON, S-CON) or occur independently of any
acute demyelinating lesion of the optic nerve (primary form of CON, P-CON). In both S-CON and
P-CON, a long term progressive ganglion cell axonal loss occurs. This axonal damage could be
secondary to retrograde atrophy of axons within plaques of demyelination or a primary
progressive degeneration of ganglion cells, but the underlying physiopathology has not been
fully questioned in the different profile types of CON.
In this project, investigators aim at understanding the pathophysiology of S-CON and P-CON,
i.e. secondary to demyelination or primary degeneration, in patients complaining of
persistent visual complaints. In a first cross sectional study, 30 MS patients with mild to
moderate P-CPON or S-CON and 30 age-matched control subjects will perform an extensive
neuro-ophthalmological assessment including clinical examination, visual evoked potentials
(pattern and low contrast), electroretinogram (pattern and multifocal ERG), OCT
(peripapillary and macular volume scan segmentation protocols) and MRI of the optic nerve. In
these patients with mild to moderate CON, investigators aim at differentiating patients
showing predominant demyelination from those showing pure or predominant axonal degeneration.
Visual function assessment and degree of axonal degeneration will be compared and correlated
in the two types of underlying pathophysiology and in the group of control subject. In a
following longitudinal study, the patients will be re-assessed a year later in order to
evaluate the progression of CON in both profile types. Our hypothesis would be that visual
function and progression is worse in the degeneration group as compared to the demyelination
group. This study should help to find reliable measures of the pathophysiology of CON and
correlate it with the long-term visual prognostic of the disease.
| Status | Completed |
| Enrollment | 39 |
| Est. completion date | August 2016 |
| Est. primary completion date | August 2016 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Inclusion criteria for patients - All patients may have a clinically definite, laboratory-supported diagnosis of multiple sclerosis according to the Mac Donald criteria (2010). - All patients may present a chronic visual complaint. - All patients may present mild to moderate chronic optic neuropathy (cf infra) - All patients may not have recent acute optic neuritis (<2 years) - All patients will be informed about the design and purpose of the study, and all will give their informed, written consent to the protocol, which may have been approved by the local ethics committee. - Age: > 18 - Able to understand the instructions - Having a health coverage - Able to sit down for 1 hour Diagnosis of mild to moderate chronic optic neuropathy For the diagnosis of optic neuropathy, patients will have to meet 3 of the 6 next criteria: 1. Far Visual Acuity (ETDRS charts, 100% contrast) < 85 letters 2. Far Visual Acuity (ETDRS charts, 2.5% contrast) < 60 letters 3. Mean visual field defect on static perimetry> 2dB 4. Mean pRNFL in OCT < 80 µ. 5. Color vision score > 35 6. Disc pallor Diagnosis of mild to moderate optic neuropathy - Far Visual Acuity (ETDRS charts, 100% contrast) >70 letters Diagnosis of chronic optic neuropathy - Stable or worsening of visual acuity, visual field and/or RNFL in OCT, at 6 month of interval - Inclusion criteria for controls - Age > 18 years - Visual acuity score (ETDRS) > 85 - Able to understand the instructions - Having a health coverage - Informed and consenting to give his written consent Exclusion Criteria: - Non inclusion criteria for patients. - Ophthalmological - Other ophthalmological disorder that could impair corrected visual acuity (Maculopathy, Retinopathy…) - Ocular instability in primary position of gaze - Neurological - Ongoing seizure - Severe handicap that does not allow sitting down position for 1 hour - General - Unstable medical state - Severe renal insufficiency - Allergy to gadolinium - Claustrophobia - Implanted electrical stimulator (pace maker) - Metallic prosthesis or orthesis, cochlear implants - Intraocular foreign material - Pregnancy (on questioning) - Tutelage or any legal protection measure - Non inclusion criteria for controls - Any ophthalmological disorder that could impair corrected visual acuity - Any neurological disorder - MRI contraindication - Allergy to gadolinium - Severe renal insufficiency - Claustrophobia - Implanted electrical stimulator (pace maker) - Metallic prosthesis or orthesis, cochlear implants - Intraocular foreign material - Pregnancy (on questioning) - Tutelage or any legal protection measure |
| Country | Name | City | State |
|---|---|---|---|
| France | Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON | France | Bron |
| Lead Sponsor | Collaborator |
|---|---|
| Hospices Civils de Lyon | Fondation pour la Recherche Médicale |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change from Day0 15' P100 VEP latency at one year | 15' VEP latency may be the best outcome that allow differentiating patients from controls, and each of the sub-group of patients | D0 and one year | |
| Secondary | Change from Day0 100%, 2.5% and 1.25% ETDRS Visual Acuity at one year (composite measure) | D0 and one year | ||
| Secondary | Change from Day0 Visual field macular threshold and corrected mean visual field deficit at one year (composite measure) | D0 and one year | ||
| Secondary | change frome Day0 NEI-VFQ 25 composite score and 10-item score at one year (composite measure) | D0 and one year | ||
| Secondary | Change from Day0 N75, P100, N135 VEP latency and amplitude; P50, N95 ERG latency and amplitude; p1 mERG latency and amplitude at one year (composite measure) | D0 and one year | ||
| Secondary | Change from Day0 OCT peripapillary RNLF thickness and Ganglion cell layer average thickness on macular dense volume at one year (composite measure) | D0 and one year | ||
| Secondary | MRI presence or absence of optic nerve inflammatory signs on diameter of the optic nerve | D0 |